Skip to main content

Table 2 Evaluation and comparison of drug resistance rate of anti-tuberculosis drugs in 2014–2019

From: Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hainan, China: from 2014 to 2019

Category 2014 n (%) 2015 n (%) 2016 n (%) 2017 n (%) 2018 n (%) 2019 n (%) Total n (%) χ2 P
All TB cases
 Any drug-resistance 95 (42.6) 85 (49.7) 60 (56.1) 96 (50.5) 127 (38.4) 195 (42.2) 658 (44.3) 16.820 0.005
 INH 71 (31.8) 67 (39.2) 42 (39.3) 68 (35.8) 85 (25.7) 132 (28.6) 465 (31.3) 16.349 0.006
 RIF 60 (26.9) 63 (36.8) 48 (44.9) 68 (35.8) 86 (26.0) 136 (29.4) 461 (31.1) 20.521 0.001
 EMB 23 (10.3) 12 (7.0) 20 (18.7) 26 (13.7) 26 (7.9) 41 (8.9) 148 (10.0) 15.941 0.007
 STR 48 (21.5) 39 (22.8) 24 (22.4) 50 (26.3) 56 (16.9) 98 (21.2) 315 (21.2) 6.977 0.222
 MDR 54 (24.2) 50 (29.2) 38 (35.5) 53 (27.9) 63 (19.0) 111 (24.0) 369 (24.9) 15.430 0.009
 Any second-line drug resistance 42 (18.8) 43 (25.1) 34 (31.8) 46 (24.2) 47 (14.2) 96 (20.8) 308 (20.8) 20.435 0.001
 CPM 2 (0.9) 3 (1.8) 3 (2.8) 7 (3.7) 6 (1.8) 21 (4.5) 42 (2.8) 10.443 0.064
 KAR 6 (2.7) 5 (2.9) 7 (6.5) 13 (6.8) 6 (1.8) 14 (3.0) 51 (3.4) 13.119 0.022
 OFX 38 (17.0) 41 (24.0) 33 (30.8) 42 (22.1) 43 (13.0) 76 (16.5) 273 (18.4) 24.208 < 0.001
 PTO 1 (0.4) 1 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 18 (3.9) 20 (1.3) 34.796 < 0.001
 XDR 4 (1.8) 3 (1.8) 5 (4.7) 10 (5.3) 4 (1.2) 7 (1.5) 33 (2.2) 11.580 0.041
New cases
 Any drug-resistance 35 (28.0) 22 (25.0) 13 (33.3) 29 (30.9) 47 (24.0) 67 (23.7) 213 (25.8) 3.759 0.585
 INH 22 (17.6) 14 (15.9) 6 (15.4) 17 (18.1) 27 (13.8) 36 (12.7) 122 (14.8) 2.813 0.729
 RIF 15 (12.0) 8 (9.1) 7 (17.9) 13 (13.8) 23 (11.7) 28 (9.9) 94 (11.4) 3.181 0.672
 EMB 6 (4.8) 2 (2.3) 1 (2.6) 4 (4.3) 6 (3.1) 11 (3.9) 30 (3.6) 1.462 0.917
 STR 17 (13.6) 9 (10.2) 6 (15.4) 13 (13.8) 25 (12.8) 31 (11.0) 101 (12.2) 1.604 0.901
 MDR 14 (11.2) 4 (4.5) 5 (12.8) 8 (8.5) 15 (7.7) 25 (8.8) 71 (8.6) 4.210 0.520
 Any second-line drug resistance 13 (10.4) 7 (8.0) 7 (17.9) 11 (11.7) 12 (6.1) 26 (9.2) 76 (9.2) 6.397 0.270
 CPM 1 (0.8) 1 (1.1) 0 (0.0) 3 (3.2) 3 (1.5) 7 (2.5) 15 (1.8) 4.133 0.530
 KAR 2 (1.6) 1 (1.1) 0 (0.0) 4 (4.3) 1 (0.5) 6 (2.1) 14 (1.7) 6.696 0.244
 OFX 10 (8.0) 7 (8.0) 7 (17.9) 8 (8.5) 10 (5.1) 17 (6.0) 59 (7.2) 7.388 0.193
 PTO 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7) 2 (0.2) 4.289 0.509
 XDR 0 (0.0) 1 (1.1) 0 (0.0) 1 (1.1) 0 (0.0) 1 (0.4) 3 (0.4) 4.383 0.496
Retreatment cases
 Any drug-resistance 60 (61.2) 63 (75.9) 47 (69.1) 67 (69.8) 80 (59.3) 128 (71.5) 445 (67.5) 10.236 0.069
 INH 49 (50.0) 53 (63.9) 36 (52.9) 51 (53.1) 58 (43.0) 96 (53.6) 343 (52.0) 9.512 0.090
 RIF 45 (45.9) 55 (66.3) 41 (60.3) 55 (57.3) 63 (46.7) 108 (60.3) 367 (55.7) 14.257 0.014
 EMB 17 (17.3) 10 (12.0) 19 (27.9) 22 (22.9) 20 (14.8) 30 (16.8) 118 (17.9) 9.294 0.098
 STR 31 (31.6) 30 (36.1) 18 (26.5) 37 (38.5) 31 (23.0) 67 (37.4) 214 (32.5) 10.845 0.055
 MDR 40 (40.8) 46 (55.4) 33 (48.5) 45 (46.9) 48 (35.6) 86 (48.0) 298 (45.2) 10.328 0.066
 Any second-line drug resistance 29 (29.6) 36 (43.4) 27 (39.7) 35 (36.5) 35 (25.9) 70 (39.1) 232 (35.2) 10.741 0.057
 CPM 1 (1.0) 2 (2.4) 3 (4.4) 4 (4.2) 3 (2.2) 14 (7.8) 27 (4.1) 10.541 0.061
 KAR 4 (4.1) 4 (4.8) 7 (10.3) 9 (9.4) 5 (3.7) 8 (4.5) 37 (5.6) 6.544 0.257
 OFX 28 (28.6) 34 (41.0) 26 (38.2) 34 (35.4) 33 (24.4) 59 (33.0) 214 (32.5) 8.806 0.117
 PTO 1 (1.0) 1 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 16 (8.9) 18 (2.7) 35.332 < 0.001
 XDR 4 (4.1) 2 (2.4) 5 (7.4) 9 (9.4) 4 (3.0) 6 (3.4) 30 (4.6) 7.670 0.175
  1. Abbreviation: INH, isoniazid; RIF, rifampin; EMB, ethambutol; STR, streptomycin; first-line drug resistance, including isoniazid, rifampin ethambutol and streptomycin; MDR, multi-drug resistant; CPM, capreomycin; KAR, kanamycin; OFX, ofloxacin; PTO, protionamide; XDR, extensively drug-resistant